-
In a series of consecutive patients with locally advanced rectal cancer, a novel treatment regimen was studied that involved "induction chemotherapy" followed by chemoradiotherapy prior to total mesorectal excision. The investigators found a high local control rate and promising disease-free and overall survival outcomes.
-
There has long been an appreciation of the risk of cognitive decline associated with chemotherapy but questions remain about the magnitude and duration of the observed deficits. In this meta-analysis of studies that included neuropsychological assessments at a minimum of 6 months after completion of breast cancer chemotherapy, definite but small deficits were found for both verbal and visuospatial capabilities. In this analysis, age and educational status were not found to be moderators of acquired deficits.
-
-
Women who last give birth at age 40 or older have a 44% decreased risk of endometrial cancer when compared to women who have their last birth under the age of 25, according to results of a new international study.1
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
Apropos of the recent emphasis on discouraging elective deliveries prior to 39 weeks, a group from Cincinnati embarked on a study to determine whether steroids had any neonatal benefit in patients delivering between 34 and 39 weeks who had immature amniotic fluid lung profiles.
-
The authors performed a prospective cohort study, the contraceptive CHOICE Project, in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
Public health officials are sounding the alarm on the growing threat of multi-drug resistant gonorrhea. What will it take to turn the tide against gonorrhea, the second most commonly reported communicable disease in the United States?
-
Another oral contraceptive (OC) packaging alert has been issued. Check your clinic's stock for norgestimate and ethinyl estradiol birth control pills distributed by Glenmark Generics.
-
African-American women at risk for HIV are the focus of a new prevention program launched by the Centers for Disease Control and Prevention (CDC). "Take Charge. Take the Test" is running in 10 cities where such women are especially hard-hit by the disease.